[Clinical study of ambulatory patient cancer chemotherapy for advanced colorectal cancer].
To evaluate ambulatory patient cancer chemotherapy, the clinical response, toxicities and survival time were analysed among 19 patients with non-curative or recurrent colorectal cancer who were treated by Uracil/Tegafur (UFT) plus oral Leucovorin (UZEL) for the past 2 years. The patients were administered UFT (300 mg/m2/day) and UZEL (75 mg/body/day) for 28 days with a one-week interval every 35 days as one course.A partial response (PR) was observed in 6 patients (31.6%) and stable disease (SD) in 8. The median survival time was 16 months. Although nausea/vomiting, diarrhea and leucopenia were noted, no severe side effects were observed. These results suggested that UFT plus Leucovorin therapy might be a useful cancer chemotherapy for ambulatory patients with advanced colorectal cancer.
Toyokawa
Akihiro
A
Dept. of Surgery, Yodogawa Christian Hospital.
Tsujimura
Toshiaki
T
Hamabe
Yutaka
Y
Sato
Shunsuke
S
Mukubou
Hideyo
H
Wakahara
Tomoyuki
T
Kaji
Masahide
M
Tsukamoto
Tadashi
T
Wakita
Kazuyuki
K
Onishi
Norihito
N
Ishida
Takeshi
T
Watanabe
Akihiko
A
Fujiwara
Hitoshi
H
Mukai
Hidekazu
H
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D013280:Stomatitis / Q000139:chemically induced; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
D004338:Drug Combinations; C096910:UFT(R) drug; D005641:Tegafur; D014498:Uracil; D002955:Leucovorin